(Reuters) – Europe’s medicines regulator said on Friday that an antibody drug combination developed by Regeneron Pharmaceuticals can be used to treat COVID-19 patients who do not require oxygen support and are at high risk of progressing to severe illness.
The recommendation can now be used for guidance in individual European nations on the possible use of the combination of casirivimab and imdevimab before a marketing authorisation is issued, the European Medicines Agency said. (https://bit.ly/3syYgzB)
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Shounak Dasgupta)
